Developing Novel Therapies for Neuropsychiatric Diseases

We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, for the treatment of schizophrenia and other neuropsychiatric diseases.

Learn MoreClinical Programs

About Us

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases.

Learn More

For Patients & Providers

We are evaluating the safety and efficacy of LB-102 in patients with acute schizophrenia.

Explore Our Clinical Trials

LB Pharma’s leading innovation

LB Pharma's lead asset and the foundation of the company's growth is LB-102, N-Methyl amisulpride. If approved by the FDA, LB-102 would be the first benzamide atypical approved to treat schizophrenia for the US market.

READ MORE ABOUT LB-102

Want to learn more about LB Pharma?

CONNECT NOW
Would you like to receive news & updates from us automatically by email?

Join our mailing list